ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Corcept Therapeutics, Inc. ?
1
High Management Efficiency with a high ROE of 21.09%
2
Company has a low Debt to Equity ratio (avg) at times
3
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 21.09%
4
Negative results in Jun 25
- CASH AND EQV(HY) Lowest at USD 664.99 MM
- DEBT-EQUITY RATIO (HY) Highest at -52.79 %
5
With ROE of 19.39%, it has a expensive valuation with a 11.40 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 36.00%, its profits have risen by 13.1% ; the PEG ratio of the company is 5.4
6
High Institutional Holdings at 87.23%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
7
Market Beating performance in long term as well as near term
- Along with generating 36.00% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Corcept Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Corcept Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Corcept Therapeutics, Inc.
41.88%
1.24
121.87%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
15.31%
EBIT Growth (5y)
-6.28%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.47
Sales to Capital Employed (avg)
0.97
Tax Ratio
1.56%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
87.23%
ROCE (avg)
111.37%
ROE (avg)
21.09%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
59
Industry P/E
Price to Book Value
11.40
EV to EBIT
67.34
EV to EBITDA
66.34
EV to Capital Employed
20.65
EV to Sales
10.89
PEG Ratio
5.37
Dividend Yield
NA
ROCE (Latest)
30.67%
ROE (Latest)
19.39%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 182.2 MM
RAW MATERIAL COST(Y)
Fallen by 0.24% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 1.13 times
NET SALES(Q)
Highest at USD 194.43 MM
-2What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 664.99 MM
DEBT-EQUITY RATIO
(HY)
Highest at -52.79 %
Here's what is working for Corcept Therapeutics, Inc.
Operating Cash Flow
Highest at USD 182.2 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 194.43 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Inventory Turnover Ratio
Highest at 1.13 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by 0.24% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Corcept Therapeutics, Inc.
Cash and Eqv
Lowest at USD 664.99 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -52.79 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
